This site is intended for Healthcare Professionals only.

New Medicine Service expanded to cover 12 new conditions from September 1

Date:

Share post:

The new medicine service (NMS) will be expanded to cover 12 new therapeutic conditions from September 1, the Pharmaceutical Services Negotiating Committee (PSNC) informed today (August 23), as it published the outcome of the negotiations on Year Three of the community pharmacy contractual framework.

From September 1, contractors can offer patients support to manage twelve additional conditions:

  • Acute coronary syndrome (ACS);
  • Atrial fibrillation (AF);
  • Coronary heart disease;
  • Epilepsy;
  • Glaucoma;
  • Gout;
  • Heart failure;
  • Hypercholesterolaemia ;
  • Osteoporosis;
  • Parkinson’s Disease;
  • Stroke / transient ischemic attack; and
  • Urinary incontinence and retention.

The conditions previously covered by the service will remain in place, PSNC said, adding that the NHS Business Services Authority (NHSBSA) will shortly publish an updated list of medicines that are suitable for NMS, covering the above conditions.

After the expansion to the service, an increase in the cap on the number of NMS which can be provided by contractors has also been agreed, the negotiator said.

“The cap will be increased from 0.5 per cent to one per cent of monthly prescription volume and additional bandings will also be included. The maximum remuneration for the service remains at £28 per NMS.”

Besides, the service will be amended to allow the opportunity for NMS to be offered to support carers of patients and the parents or guardians of children newly prescribed medication who could benefit from the service but where the patient is not able to provide informed consent themselves.

Catch-up NMS

As part of the NHS Covid-19 recovery plan, the temporary introduction of catch-up NMS has been agreed. This will enable patients, who were prescribed a new medicine during the pandemic, but could not receive NMS support at the time, to access a catch-up NMS.

Future development

Further therapeutic areas will be piloted through the Pharmacy Integration Fund to inform any future expansion of the service. This will support the further development of the service as part of a service model fully integrated with the wider Primary Care.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Boots supports community pharmacists become Mental Health First Aiders

PDA encourages representatives at Boots to undertake Mental Health First Aid (MHFA) training Pharmacists, who are working on the...

Surge in stroke cases could cost UK £75bn by 2035, charity warns

By 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day...

NHS and i.AI forge historic collaboration to boost healthcare

AI assisting NHS to half treatment times for stroke patients and overall patient care experience The Department of Health...

NHS to cut the red tape to support 50K NHS postgraduate doctors

New measures are part of NHS' broader efforts to retain its skilled workforce and ensure high-quality patient care  In...